Less than six months after securing hundreds of millions of dollars in financing to advance its oral GLP-1 program, Corxel Pharmaceuticals has reported encouraging midstage results that strengthen the case for further development of its lead obesity candidate.
The biotech announced June 23 that its oral small-molecule GLP-1 therapy, CX11, produced weight loss of nearly 12% in a U.S. phase 2 trial involving adults with obesity or individuals who were overweight and had at least one obesity-related comorbidity.
The study had 246 participants and evaluated four separate dosing regimens of CX11 against placebo. The trial achieved its primary objectives, demonstrating statistically significant reductions in body weight from baseline compared with placebo.
After 36 weeks of treatment, participants receiving CX11 experienced weight loss of as much as 11.5%, with the company noting that weight reduction continued without signs of reaching a plateau.
Corxel also highlighted the drug’s safety and tolerability profile. Rates of nausea ranged between 33% and 34%, vomiting between 12% and 16%, diarrhea between 4% and 12%, and constipation between 2% and 12%. No hugely adverse gastrointestinal events were reported. Treatment discontinuations related to gastrointestinal side effects occurred in 5% of participants, while investigators observed no signs of liver-related safety concerns.
The company obtained rights to develop and commercialize the drug outside China from Vincentage in late 2024. Last month, Vincentage reported an over 12% weight loss after one year in a phase 3 obesity study conducted in China, paving the way for potential regulatory submissions in that market.
Chief Medical Officer Bo Liang said the U.S. findings align closely with the efficacy and safety profile previously demonstrated in the Chinese late-stage program. He added that the combined data from both studies increase the company’s confidence in CX11 and support its goal of delivering an effective, flexible and well-tolerated oral treatment option for patients worldwide.
With positive results now available from both the China phase 3 and U.S. phase 2 studies, Corxel plans to use proceeds from its recent Series D financing to launch global pivotal phase 3 trials aimed at securing approval for weight management.
As the company advances CX11 into late-stage development, it enters an increasingly competitive race among developers of oral GLP-1 therapies. Earlier in June, AstraZeneca reported that its oral small-molecule GLP-1 receptor agonist elecoglipron produced average weight loss of over 10% after 26 weeks in a phase 2b study, prompting the company to move the candidate into phase 3 testing.
Structure Therapeutics is also advancing its oral GLP-1 candidate, aleniglipron, which has demonstrated weight loss of over 15% after 44 weeks of treatment. Chief Executive Officer Raymond Stevens previously described that outcome as the strongest weight-loss result reported to date for an oral GLP-1 receptor agonist, and the company is preparing for its own late-stage clinical program.
Meanwhile, companies such as Ambrosia and BrightGene continue to develop earlier-stage oral GLP-1 candidates, all seeking to challenge the dominant positions established by Eli Lilly and Novo Nordisk in the rapidly expanding obesity treatment market.
Corxel is positioning itself as an emerging competitor in the global metabolic disease market following encouraging Phase 2 clinical trial results for its oral GLP-1 therapy. The positive findings strengthen the company’s pipeline and support its strategy to expand internationally in the highly competitive obesity and type 2 diabetes treatment landscape.
With demand for convenient oral therapies continuing to rise, Corxel is attracting attention from investors, healthcare professionals, and pharmaceutical partners seeking next-generation GLP-1 medicines.
Corxel Achieves Positive Oral GLP-1 Phase 2 Results
The latest Phase 2 study demonstrated promising efficacy and safety outcomes for Corxel’s oral GLP-1 candidate. Patients receiving the investigational treatment experienced clinically meaningful improvements in metabolic markers, while the therapy maintained a favorable tolerability profile.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
